Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 24 papers were listed this time. We've singled out a methods paper on QALY imputation, a value of information analysis, a couple of meta-analyses with associated economic evaluations and an evaluation in Type 1 diabetes:
Purmonen TT, P Nk L Inen E, Turunen JH, Asseburg et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011 Feb 8. [Epub ahead of print] PMID: 21299447.
Jeroen L, Christiaan M, Niel H, et al. Imputing QALYs from Single Time Point Health State Descriptions on the EQ-5D and the SF-6D: A Comparison of Methods for Hepatitis A Patients. Value Health. 2011 Feb 4. [Epub ahead of print] PMID: 21296602.
Grosso AM, Bodalia PN, Macallister RJ, et al. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011 Mar;65(3):253-63. PMID: 21284790.
Klersy C, De Silvestri A, Gabutti G, et al. Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail. 2011 Feb 1. [Epub ahead of print] PMID: 21193439.
Valentine WJ, Aagren M, Haglund M, et al. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scand J Public Health. 2011 Feb;39(1):79-87. PMID: 20688795.
